Intuitive Surgical, Inc. ranks slightly below the peer group median, with a relatively even profile across the main dimensions. The market setup has weakened, with clear trend damage and relative performance under pressure. Price behavior is partially reflecting the structural picture, with a moderate gap remaining.
Peer-relative scores, weakest to strongest
Intuitive Surgical develops and sells robotic-assisted surgical systems, most notably the da Vinci platform. The company generates revenue from system sales, instruments, accessories, and related services.
Top-tier profitability is clear at a 21.2% ROIC and 30.2% operating margin, yet Intuitive Surgical’s premium valuation is under pressure as market confidence and stability decline. The company’s robust capital efficiency and double-digit revenue growth have supported a forward P/E of 41.1x, but persistent signals of market unease—reflected in a near-50% max drawdown, a trend score of just 20/100, and a stability score of 46/100—indicate fragility in the premium.
While Q4 2025 brought both EPS and revenue beats, these positive surprises have not resulted in lasting market reassurance. The premium remains exposed: analyst buy ratings persist, but the valuation gap versus the peer median (25.1x) is amplified by recent volatility and the market’s sensitivity to risk. The company’s strong financial delivery is a positive signal, but restoring confidence after such pronounced drawdowns and ongoing instability remains unresolved.
External context complicates the picture. The FDA’s March 2026 review of da Vinci stapler safety introduces a product-specific risk that weighs more heavily on Intuitive Surgical than on less capital-intensive peers. At the same time, proposed FY27 CMS reimbursement changes threaten to directly impact system adoption, increasing uncertainty for a business model closely tied to hospital capital budgets. Recent analyst sentiment and sector trends support the execution story. However, these regulatory and reimbursement stressors mean the premium has not yet stabilized.
Compared to peers, Intuitive Surgical’s high valuation is not unique within the sector, but the intensity of recent product and regulatory overhangs, combined with a sharper drawdown, make the situation more challenging than for many direct competitors. These pressures are partly driven by factors specific to Intuitive Surgical, especially its exposure to capital equipment cycles and regulatory scrutiny.
A more defensible premium would require market confidence to stabilize and volatility to normalize. Supporting improvement would include a favorable FDA safety review and clarity on CMS reimbursement policy. Until then, Intuitive Surgical carries a valuation that remains under pressure.
Break down ISRG's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.